Botulism -- China
"Significant rates of dysphagia were documented in the medical officer's clinical reviews of both Myobloc (October 1999) (12) and Botox therapeutic (November 1999) (13). In most studies, patients had previously been exposed to botulinum toxin. Since those with previous adverse events would presumably be less likely to enroll in subsequent trials, the incidence of dysphagia may be underestimated.
"Botox: There was only one RCT [randomized controlled trial] for Botox therapeutic that was
Read more about it at HealthMap Global Disease Alerts via http://healthmap.org/ln.php?8654975&promed&0
No comments:
Post a Comment